Aclaris Therapeutics, Inc. (ACRS) Balance Sheet

The sequential decline in total assets, from $198.7M in 2026Q1 to $179.7M in 2026Q2, reflects continued operating losses and a reduction in cash reserves. Equity also contracted from $155.6M in 2024Q4 to $124.6M in 2026Q2, driven by cumulative net losses exceeding $1.0B in retained earnings. This trajectory suggests the balance sheet is weakening, with no apparent offsetting asset accumulation, indicating a reliance on external financing to sustain operations.

The absence of debt on the balance sheet provides no leverage risk, but it also means the company has no financial cushion beyond its equity base. The slight debt in prior quarters (e.g., $2.0M in 2026Q1) appears to be a short-term facility, likely repaid by 2026Q2. Given the high cash burn, the company may need to raise capital through equity issuance, which would dilute existing shareholders, as suggested by the declining equity trend.

The balance sheet shows no goodwill and negligible property, plant, and equipment, which is typical for a clinical-stage biotech. The asset base is primarily composed of cash and other current assets, reflecting a business model that invests in intellectual property and clinical trials rather than fixed assets. This structure provides flexibility but also means the company has little collateral for debt financing, reinforcing its dependence on equity markets.

The equity base is being eroded by cumulative losses, with retained earnings becoming increasingly negative. The decline in equity from $155.6M in 2024Q4 to $124.6M in 2026Q2 indicates that the company is consuming capital at a rapid pace. While there is no evidence of share repurchases or dividends, the potential for future dilution is high if the company needs to raise funds, which would further pressure equity per share.

The current ratio of 3.46 in 2026Q2 suggests adequate short-term liquidity, but the absolute cash position is critically low relative to the quarterly operating loss of approximately $20M. The rapid decline in cash from $28.7M to $19.2M in one quarter indicates a burn rate that exceeds the available cash, implying an imminent need for additional financing. The current ratio is misleading because it includes receivables and other current assets that may not be easily convertible to cash, so the cash runway is the more relevant metric.